Full text not available from this repository.
Systemic sclerosis (scleroderma, SSc) and mixed connective tissue disease (MCTD) are chronic autoimmune diseases characterised by a broad spectrum of clinical manifestations including different forms of musculoskeletal involvement, skin and vascular changes, as well as internal organ complications. Clinical course and outcomes might vary from mild forms with good clinical prognosis to severe rapidly progressive life-threatening diseases. At present, immunosuppressive therapies are considered a cornerstone in the treatment of MCTD, and are frequently used in clinical practice in SSc despite limited evidence from clinical trials. The aim of the present review is to discuss available data concerning efficacy of methotrexate therapy in SSc and MCTD.
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine|
|DDC:||610 Medicine & health|
|Deposited On:||02 Feb 2011 15:42|
|Last Modified:||27 Nov 2013 20:40|
|Publisher:||Clinical And Experimental Rheumatology S.A.S.|
|Citations:||Web of Science®. Times Cited: 3|
Scopus®. Citation Count: 4
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page